{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T19:41:43Z","timestamp":1786650103811,"version":"build-2736575974"},"reference-count":10,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2015,10]]},"abstract":"<jats:p>Advanced gastric cancer has a poor prognosis, and only chemotherapy improves survival. Further chemotherapy after progression is controversial. Eastern Cooperative Oncology Group performance status is an important indicator for new chemotherapy decision. Complete response (CR) after recurrent disease is very rare, but could occur in some cases with chemotherapy. The 68-year-old male received chemotherapy for metastatic gastric adenocarcinoma. He received epirubicin, cisplatin and fluorouracil in the first line, capecitabine in the second line and cisplatin-capecitabine in the third line. CR was observed after third-line chemotherapy with four courses. Mediastinal and abdominal metastases were completely resolved. We decided to report this patient because it is very unusual to achieve CR in a patient in whom the best supportive care might be reasonable.<\/jats:p>","DOI":"10.4103\/0973-1482.150348","type":"journal-article","created":{"date-parts":[[2016,2,19]],"date-time":"2016-02-19T01:07:21Z","timestamp":1455844041000},"page":"1026-1026","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["A case of gastric cancer with liver metastases had a complete response with cisplatin and capecitabine as third-line chemotherapy"],"prefix":"10.4103","volume":"11","author":[{"given":"Fatih","family":"Teker","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, 19 Mayis University Medical Faculty, Samsun, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fevziye","family":"Canbaz","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, 19 Mayis University Medical Faculty, Samsun, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasemin","family":"Kemal","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, 19 Mayis University Medical Faculty, Samsun, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Idris","family":"Yucel","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, 19 Mayis University Medical Faculty, Samsun, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2016,2,15]]},"reference":[{"key":"R1-20260109","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S1470-2045(08)70035-4","article-title":"S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): A phase III trial","volume":"9","author":"Koizumi","year":"2008","journal-title":"Lancet Oncol"},{"key":"R2-20260109","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1200\/JCO.2004.08.154","article-title":"Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer \u2013 pooled analysis from three multicenter, randomized, controlled trials using individual patient data","volume":"22","author":"Chau","year":"2004","journal-title":"J Clin Oncol"},{"key":"R3-20260109","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s10120-011-0117-2","article-title":"Three-week combination chemotherapy with S-1 and cisplatin as first-line treatment in patients with advanced gastric cancer: A retrospective study with 159 patients","volume":"15","author":"Koo","year":"2012","journal-title":"Gastric Cancer"},{"key":"R4-20260109","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1159\/000355690","article-title":"Sequential chemotherapies for advanced gastric cancer: A retrospective analysis of 111 patients","volume":"85","author":"Elsing","year":"2013","journal-title":"Oncology"},{"key":"R5-20260109","doi-asserted-by":"crossref","first-page":"2850","DOI":"10.1093\/annonc\/mdt351","article-title":"Second-line chemotherapy versus supportive cancer treatment in advanced gastric cancer: A meta-analysis","volume":"24","author":"Kim","year":"2013","journal-title":"Ann Oncol"},{"key":"R6-20260109","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/1756-9966-32-67","article-title":"FOLFIRI as a second-line therapy in patients with docetaxel-pretreated gastric cancer: A historical cohort","volume":"32","author":"Maugeri-Sacc\u00e0","year":"2013","journal-title":"J Exp Clin Cancer Res"},{"key":"R7-20260109","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s10637-013-0057-2","article-title":"A phase II trial of a selective c-Met inhibitor tivantinib (ARQ 197) monotherapy as a second-or third-line therapy in the patients with metastatic gastric cancer","volume":"32","author":"Kang","year":"2014","journal-title":"Invest New Drugs"},{"key":"R8-20260109","doi-asserted-by":"crossref","first-page":"297","DOI":"10.3904\/kjim.2013.28.3.297","article-title":"Design of precise third-line therapy for gastric cancer: Target or chemotherpy?","volume":"28","author":"Cho","year":"2013","journal-title":"Korean J Intern Med"},{"key":"R9-20260109","first-page":"261","article-title":"A case of recurrent gastric cancer with peritoneal dissemination responding to doxifluridine\/paclitaxel combination chemotherapy as third-line treatment","volume":"34","author":"Yagi","year":"2007","journal-title":"Gan To Kagaku Ryoho"},{"key":"R10-20260109","first-page":"1041","article-title":"Impact of clinical response to first-line chemotherapy on gastric cancer patients treated with second-line and third-line chemotherapy","volume":"58","author":"Kodera","year":"2011","journal-title":"Hepatogastroenterology"}],"container-title":["Journal of Cancer Research and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/01363817-201511040-00096","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T19:02:31Z","timestamp":1786647751000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/01363817-201511040-00096"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10]]},"references-count":10,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015]]}},"URL":"https:\/\/doi.org\/10.4103\/0973-1482.150348","relation":{},"ISSN":["0973-1482","1998-4138"],"issn-type":[{"value":"0973-1482","type":"print"},{"value":"1998-4138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,10]]}}}